Kera Capital Partners’s Kyverna Therapeutics KYTX Stock Holding History

Kera Capital Partners’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$356K	Sell	40,000 -68,083	-63%	-$604K	0.03%	430
2026 Q1	$933K	Sell	108,083 -24,520	-18%	-$204K	0.11%	96
2025 Q4	$1.06M	Sell	132,603 -289,321	-69%	-$2.15M	0.13%	84
2025 Q3	$2.53M	Hold	421,924	–	–	0.38%	54
2025 Q2	$1.3M	Buy	421,924 +45,738	+12%	+$113K	0.26%	56
2025 Q1	$726K	Buy	376,186 +55	+0%	+$163	0.22%	52
2024 Q4	$1.41M	Buy	+376,131	New	+$1.8M	0.41%	44

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $207M AUM

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Kera Capital Partners's KYTX Position: Q2 2026 in Review

Kera Capital Partners reduced its Kyverna Therapeutics (KYTX) stake by 63% in Q2 2026, selling an estimated $604K and leaving 40,000 shares worth $356K. The position accounts for 0.03% of the portfolio, ranked #430.

Kera Capital Partners first reported a position in KYTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.53M in Q3 2025. 121 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

Kera Capital Partners held 40,000 shares of Kyverna Therapeutics worth $356K as of Q2 2026.
Kera Capital Partners sold 68,083 Kyverna Therapeutics shares in Q2 2026, an estimated $604K.
Kyverna Therapeutics made up 0.03% of Kera Capital Partners's portfolio in Q2 2026, its #430 holding.
Kera Capital Partners first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 7 quarters since.
Kera Capital Partners's Kyverna Therapeutics position peaked at $2.53M in Q3 2025.
121 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Kera Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.